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A B S T R A C T
To gain insight into the role and association of cell cycle and apoptosis regulatory proteins and telomerase activity in
the course of progression of melanocitic lesions we have examined immunohistochemicaly, expression and the distribu-
tion of p53, bcl-2, Ki-67 and telomerase in 25 samples of common and dysplastic nevi, and 45 samples of primary inva-
sive melanomas. Protein p53 expression was significantly increased in dysplastic as compared with common nevi and
melanomas (p<0.001). Bcl-2 protein expression was significantly increased in melanomas as compared with common
aquired and dysplastic nevi (p=0.001). Nevi and melanomas exhibited clear-cut differences in terms of Ki-67 expression.
Telomerase expression was significantly increased in melanomas as compared with common acquired (p=0.014) and
dysplastic nevi (p<0.001). Enhanced telomerase activity in association with increased bcl-2 expression in the course of
melanoma progression could contribute to development and progression of melanoma.
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Introduction
Melanoma is the most devastating form of skin can-
cer. It is becoming clear that solar ultraviolet radiation is
a main culprit in the etiology of melanoma the same as in
basal and squamous cell carcinomas. Although sun expo-
sure probably plays a primary or supporting role in mela-
noma, etiology of these tumors is probably variable and
multifactorial. It has become clear that molecular events
regulating cell survival, growth arrest, apoptosis and cell
differentiation, are important contributors to the overall
kinetics of benign and malignant cell growth1–3. p53 pro-
tein is well-described tumor suppressor that has a cen-
tral role in the initiation of apoptosis and cell cycle con-
trol whereas Bcl-2 and its homologous proteins have
emerged as one of the most important regulators of pro-
grammed cell death, playing a crucial role in the balance
between cell survival and cell death3–6. The pro-survival
proteins such as bcl-2/bcl-x block apoptosis, whereas
bax-like proteins bax and bak induce apoptosis5–7.
On the other hand, cell proliferation capacity, tumo-
rigenesis and immortalization have been controlled by
telomerase. Telomerase is a ribonucleoprotein DNA poly-
merase that is responsible for maintaining the length of
telomeres on the end of chromosomes8. The role of telo-
meres is to protect chromosomes from degradation and
aberrant recombination during replication prolonging
the life span of the cell. This enzyme is repressed in hu-
man somatic cells, with a few exceptions, resulting in
progressive loss of telomeres and shortening of the chro-
mosome with successive cell divisions9. Finally, chromo-
somes reach a critical length at which cell division ceases,
senescence begins, and the cell ultimately undergoes
apoptosis or cell death. Contrary, telomerase is highly ex-
pressed in >85% of cancer cells including melanoma10,11.
Little is known about correlation of apoptosis regula-
tory proteins, proliferation and other biomarkers of ma-
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lignancy, such as telomerase in melanocytic lesions. Acti-
vation of telomerase and deregulation of apoptosis regu-
latory proteins contribute to pathogenesis of a signifi-
cant number of human malignances. To gain insight into
the role of cell cycle and apoptosis regulatory proteins
and telomerase activity in the course of progression of
melanocitic lesions as well as their association we have
examined expression and distribution of p53, bcl-2, Ki-67
and telomerase in common nevi, dysplastic nevi and me-
lanomas.
Materials and Methods
Patients and skin specimens
Formalin fixed, paraffin-embedded archival tissue blocks
from 50 benign melanocitic lesions (25 common acquired
nevi and 25 dysplastic nevi) and 45 melanomas (primary
invasive melanomas) were retrieved from Department of
Pathology, Rijeka University School of Medicine, Croatia.
4 m-thick sections were stained with hematoxylin-eosin
and two pathologists examined each slide independently.
Tissues were obtained from 50 (52.63%) male and 45
(47.37%) female patients. Median age of the patients was
52.10 years (range 48–69 years), 60.87 years (range 49–
71 years) and 62.50 years (range 46–76 years) for com-
mon acquired nevi, dysplastic nevi and melanoma, re-
spectively.
Immunohistochemical staining
The following antibodies and dilutions were used:
mouse monoclonal antihuman p53 antibody, DO7 (DA-
KO A/S, Glostrup, DK), at a dilution of 1:50, rabbit mo-
noclonal antihuman Ki-67 antibody, MIB-1 (DAKO A/S,
Glostrup, DK), at a dilution of 1:50, mouse monoclonal
antihuman bcl-2 antibody, Clone 124 (DAKO A/S, Glos-
trup, DK), mouse monoclonal antihuman TELOMERA-
SE (Catalitic unit-hTERT) antibody (NOVOCASTRA,
Newcastle upon Tyne, UK). Specimen of gastric cancer,
oral mucosa, lymph node and tonsil served as positive
control samples for p53, Ki-67, bcl-2 and telomerase, re-
spectively. Additional sections were run in parallel with
omission of the primary antibodies and served as nega-
tive control.
Paraffin-embedded tissue sections were deparaffini-
zed in xylene and rehydrated by washing in absolute and
diluted ethyl alcohol and distilled water. Staining of p53,
Ki-67 and bcl-2 proteins was carried out after sections
were treated with antigen retrieval solution (DAKO Chem
Mate, Glostrup, DK) at a dilution of 1:9 and placed in mi-
crowave for 20 minutes for antigen retrieval. This was
followed by the standard ABC (avidin-biotin complex)
procedure for 130 minutes in DAKO Techmate Immu-
nostainer (Techmate Horizon, serial No. 30097, LJL Bio-
systems Inc., USA).
Immunostaining results of p53, Ki-67 and bcl-2 were
quantified and expressed as percentage of positive kera-
tinocytes out of 1000 cells counted in each section. For
telomerase the extent of staining was independently
evaluated by two observers and recorded semi-quantita-
tively as determined by the percentage of lesional cells
(0%/–, 1–25%/1+, 26–75%/2+, and >75%/3+) as descri-
bed previously10. The intensity of telomerase staining
was graded as follows: 0 (negative), 1+ (weakly positive),
2+ (moderately positive), and 3+ (intensively positive)
as described previously10. Counting fields were randomly
selected to minimize possible bias.
Statistics
The normality of data was tested using Kolmogorov-
Smirnov test. Since the distributions were normal, the
results were presented as mean ± standard deviation
and 95% confidence intervals. We used the parametric
test one-way ANOVA to compare differences in p53, bcl-2
and Ki-67 expression between tested groups, and Tukey-
HSD test for post-hoc analysis. We computed the correla-
tion matrix using Pearson’s product-moment correlation
for analysis of correlations between positively stained of
p53, Ki-67, bcl-2 proteins and telomerase in all three
groups.
All statistical analyses were performed using Statis-
tica for Windows (release 6.1., StaSoft. Inc., Tulsa, OK,
USA). The level of statistical significance was set at 0.05.
Results
Nuclear staining for p53 protein was present in 35%
of common nevi, 48% of dysplastic nevi and 47% of mela-
nomas. Positive p53 cells were distrubuted in a diffuse
pattern throughout melanocytic lesions. Expression val-
ues of p53, Ki-67, bcl-2 and telomerase are shown in Fig-
ure 1. Protein p53 expression was significantly increased
in dysplastic nevi as compared with common nevi and
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Fig. 1. Expression of p53, Ki-67, bcl-2 and
telomerase in melanocitic lesions.*for p53, Ki-67, bcl-2
and telomerase statistical significance is p<0.0001.
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melanomas (p<0.001). The lowest values were detected
in common nevi and were significantly lower as com-
pared with melanomas (p<0.001).
Nuclear expression of Ki-67 protein was detected in
all cases examined. Ki-67 positivity showed same distri-
bution pattern as p53-positivity in common and dyspla-
stic nevi and melanomas. We also found some positivity
in dysplastic and morphologically normal skin surround-
ing dysplastic nevi and especially melanomas. Nevi and
melanomas exhibited clear-cut differences in terms of
Ki-67 expression. The most intense cell proliferation was
detected in melanomas and was significantly increased
as compared to both nevi groups (p<0.0001). Also, Ki-67
protein expression was significantly lower in common
nevi as compared with dysplastic nevi (p<0.0001).
Strong expression of Bcl-2 was detected in 41% of
common nevi, 46% of dysplastic nevi and 54% of mela-
noma samples, similarly to previous study6. The Bcl-2
positive cells were distributed diffusely in all melanocytic
lesions. Bcl-2 protein expression was significantly in-
creased in melanomas as compared with common ac-
quired and dysplastic nevi (p=0.001), while difference
between two nevi groups did not reach statistical signifi-
cance (p=0.680).
Human telomerase reverse transcriptase (hTERT) sta-
ining was detected in all melanocytic lesions examined as
previously shown by other studies10. Telomerase expres-
sion was significantly increased in melanomas as compared
with common acquired (p=0.014) and dysplastic nevi
(p<0.001), while the difference between the two nevi
groups did not reach statistical significance (p= 0.138). The
pattern of hTERT expression was uniform throughout the
lesions, with the same degree of staining in the lower half
as the upper half of the dermal component in benign
melanocytic nevi and melanomas (Figure 2.). Staining in-
tensity was significantly increased in melanomas as com-
pared to both nevi groups (p<0.05) and in dysplastic nevi
as compared to common nevi (p<0.05). The nucleus, espe-
cially nucleolus, showed greater staining intensity as com-
pared with the cytoplasm of the melanocytes.
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Fig. 2. Telomerase expression in common nevi, dysplastic nevi
and melanomas. a) Telomerase activity can be detected through
out common nevi (HE X200). b) Typical dysplastic nevus with
relatively high telomerase activity. Telomerase expression can be
detected uniformly throughout the lesions (HE X200). c) Inten-
sive telomerase activity in melanoma cells could be detected in all
tumour cells (HE X200).
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We found positive, statistically significant correlation
between p53 and bcl-2 expression in dysplastic nevi (p<
0.001, and r=0.531) but correlation did not reach statis-
tical significance in dermal nevi (p=0.618; r=0.077) and
in melanomas (p=0.716; r=–0.056).
In common nevi, there was a positive significant cor-
relation between Ki-67 and telomerase expression (p=
0.006; r=0.790) while correlation between bcl-2 and telo-
merase expression (p=0.890; r=0.050) and between p53
and telomerase (p=0.980; r=–0.008) did not reach statis-
tical significance.
In dysplastic nevi, correlations between telomerase
and Ki-67 expression (p=0.362; r=0.323), p53 and telo-
merase (p=0.859; r=0.064) as well as between telome-
rase and bcl-2 (p=0.627; r=–0.176) were not statistically
significant.
In all melanocytic lesions examined there was a posi-
tive correlation between p53 and Ki-67 protein expres-
sion or a tendency toward higher p53 protein expression
with increasing cell proliferation (p=0.318; p<0.05; p<
0.05; with r=0.790, r=0.531, r=0.187; for common nevi,
dysplastic nevi and melanomas, respectively).
Similarly, in melanomas correlations between telo-
merase and Ki-67 expression (p=0.318; r=0.352), p53
and telomerase (p=0.605; r=0.187) as well as between
telomerase and bcl-2 (p=0.418; r=–0.289) were not sta-
tistically significant.
Discussion
Telomerase activity has been evaluated in many tu-
mors for diagnostic purposes, and an increase has been
linked with tumor progression. Previous studies mainly
used polymerase chain reaction (PCR)-based TRAP (telo-
meric repeat amplification protocol) method or in situ
hybridization assays to quantify the level of telomerase
activity 8,11,12.
We have detected increasing trend of hTERT expres-
sion, going from common nevi to dysplastic nevi and pri-
mary melanoma which suggests a role of telomerase in
tumor progression. Our data also show some overlapping
results for hTERT expression and staining intensity in
different melanocytic lesions (melanomas and dysplastic
nevi). Thus, hTERT expression is not a reliable for dis-
crimination between benign and malignant melanocytic
lesions in paraffin-embedded tissues. All of these find-
ings are in agreement with previously published stu-
dies8,10,11.
Some studies suggested increase in bcl-2 protein ex-
pression with advancing melanoma as well as associated
increase of other anti-apoptotic proteins such as bcl-x.
These results could reflect increased malignant potential
caused by inhibition of apoptosis and growth advantage
of metastatic melanoma cells6. However, other results
suggested a decrease of anti-apoptotic proteins13 or a de-
tectable level of bcl-2 in all tissues of melanocytic ori-
gin14. Although the widespread expression of bcl-2 in
both nevi groups and melanomas implies that altered ex-
pression of this oncoprotein is not the only factor in-
volved in melanoma progression, significant increase of
bcl-2 detected in melanomas suggests its contributory
role in the process of malignant alteration and progres-
sion. Alterations in apoptotic proteins expression in asso-
ciation with increased telomerase activity probably play
a synergic role in malignant transformation and mela-
noma progression.
Significantly higher p53 protein expression in dyspla-
stic nevi as compared with melanomas suggests the ne-
cessity of other contributory factors in the course of pro-
gression to melanoma. Bcl-2 down regulation has been
shown to occur preferentially in melanoma cells with
mutated p5315. Our results are in accordance with previ-
ous studies and suggest that the p53 gene is not fre-
quently mutated in melanoma16,17. Since most genotoxic
agents act primarily via p53 to induce apoptosis, one
would expect for melanoma cells to be sensitive to DNA
damaging. However, exact cause of treatment failure in
metastatic melanoma remains unsolved. This lack of p53
mutations may be explained in part by CDKN2A aberra-
tions affecting p14ARF and also by inactivation of other
downstream apoptotic effectors16.
In vitro and in vivo studies suggested that hTERT is
downregulated by wild-type p53 and telomerase activity
upregulated by bcl-2 expression18 but we have detected
no significant correlation between p53 protein and te-
lomerase expression in examined melanocytic lesions.
These results suggest that telomerase activity is not al-
ways dependent on the presence of cell cycle regulating
as well as pro-apoptotic and anti-apoptotic proteins.
It has been suggested that telomerase reactivation is
associated with increased immunohistochemical expres-
sion of bcl-2 protein, and is thought to prevent apoptosis
in normal cells19. In examined melanocytic lesions we
have found no correlation between telomerase and bcl-2
expression confirming that telomerase reactivation is in-
dependent of bcl-2 protein expression in the course of
progression from common and dysplastic nevi to mela-
noma. On the other hand, telomerase activity has been
found to correlate with bcl-2 and bcl-xL expression as
well as with reduced apoptosis in head and neck cancer20.
A strong correlation between telomerase activity and
proliferation markers in skin melanocytic lesions sug-
gested that telomerase activity could be used as a marker
for cell proliferation as various other methods, including
Ki-67 protein expression8,11. Differences in correlation
between telomerase and proliferation markers could be
explained by recent results showing that the overex-
pression of hTERT subunit promoted stem-cell prolifera-
tion without changes in length of telomeres21,22, but
again not all proliferating cells express telomerase23.
We have detected a significant increase of Ki-67 pro-
tein expression and telomerase activity in progression
from common to dysplastic nevi and melanoma, but sig-
nificant positive correlation was detected only in com-
mon nevi, while in dysplastic lesions and melanomas
there was only a tendency of higher telomerase activity
in the faster proliferating lesions. These findings suggest
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that Ki-67 proliferation index and telomerase activity do
not always correlate significantly in all tumors, as it has
been shown previously for B-cell lymphoma24. The acti-
vation of telomerase in the absence of proportionally in-
creased proliferative activity has been suggested to re-
flect a step toward immortalization, although transfor-
mation to full-blown malignancy may require additional
molecular events11. A relation between telomerase activ-
ity and cell proliferation does exist since cell terminal dif-
ferentiation and cell-cycle exit are accompanied by te-
lomerase activity down-regulation, whereas telomerase
is re-expressed following the re-entry of quiescent cells
into the cell cycle8,9. Given the fact that cancers are het-
erogeneous and not all of their cells are telomerase-com-
petent, telomerase activity might therefore also vary ac-
cording to the percentage of proliferative cells vs. quies-
cent/differentiated and/or normal cells that are present
in a tumor sample9. It has been proposed that the regula-
tory mechanisms controlling telomerase activity in mela-
noma rely on the transcription and alternative splicing of
human telomerase25. There is evidence that telomerase
has an active anti-apoptotic role26. These findings could
explain unclear correlation between telomerase and Ki-
67 protein expression detected in dysplastic nevi and
melanomas.
Cases of cutaneous melanoma with an intermediate
Ki-67 index and high telomerase activity have been des-
cribed to follow a fatal course, whereas no progression was
observed in a case of melanoma with higher Ki-67 index
and low telomerase activity. These findings suggest that
telomerase activity correlates poorly with the Ki-67 index
while being closely related with the clinical outcome11.
Telomerase is activated and upregulated in melano-
mas as compared to its precursor lesions dysplastic and
common nevi. In majority of melanocytic lesions telome-
rase activity does not correlate with bcl-2, Ki-67 and p53
protein expression. Mechanisms that promote both cell
proliferation and cell survival appear to be activated in
melanoma but telomerase activation and bcl-2 expres-
sion are independent events. In addition to enhanced
telomerase activity and its possible anti-apoptotic roll26,
increased bcl-2 expression in the course of melanoma
progression could contribute to development and pro-
gression of melanoma.
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EKSPRESIJA PROTEINA STANI^NOG CIKLUSA, REGULATORA APOPTOZE
I TELOMERAZE U MELANOCITNIM LEZIJAMA
S A @ E T A K
Da bi dobili uvid u povezanost i ulogu proteina stani~nog ciklusa, proteina regulatora apoptoze i telomerazne aktiv-
nosti tijekom procesa napredovanja melanocitnih lezija imunohistokemijski smo ispitali razinu izra`aja i distribucije
p53, blc-2, Ki-67 i telomeraze kod 25 uzoraka obi~nih i displasti~nih nevusa i 45 uzoraka primarnih invazivnih mela-
noma. Ekspresija p53 proteina je bila statisti~ki zna~ajno pove}ana kod displasti~nih nevusa u usporedbi sa obi~nim
nevusima i melanomima (p<0.001). Razina izra`aja Bcl-2 proteina je bila statisti~ki zna~ajno pove}ana kod melanoma
u usporedbi sa obi~nim ste~enim i displasti~nim nevusima (p=0.001). Nevusi i melanomi su pokazali jasne razlike u
smislu Ki-67 ekspresije. Telomerazna ekspresija je bila statisti~ki zna~ajno pove}ana kod melanoma u usporedbi sa
obi~nim ste~enim (p=0.014) i displasti~kim nevusima (p<0.001). Pove}ana telomerazna aktivnost zajedno sa pove}a-
nom bcl-2 ekspresijom u procesu progresije melanoma mogla bi doprinijeti nastanku i razvoju melanoma.
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